Genetic Analysis Uncovers New Drug Targets for Prostate Diseases
Mendelian randomization links six biomarkers to prostate diseases and points to dexamethasone, colchicine, and metformin as repurposing candidates.
Summary
Researchers at Zhejiang University used Mendelian randomization to establish causal links between circulating biomarkers and three prostate conditions — prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Six biomarkers showed significant causal effects: URK for prostatitis; GGT and TBIL for BPH; and UCR, PHOS, and BUN for prostate cancer. By integrating drug databases, protein interaction networks, RNA sequencing, and molecular docking, the team identified MPO and TUBB as drug targets for BPH, and GATA3 and ENPP3 for prostate cancer. Drug repurposing analysis suggested dexamethasone may treat BPH, while colchicine and metformin hold promise against prostate cancer — offering a genetic roadmap for more precise prostate disease therapy.
Detailed Summary
Prostate diseases collectively affect tens of millions of men worldwide, yet the molecular mechanisms linking systemic biomarkers to disease development remain incompletely understood. Identifying causal — rather than merely correlational — biomarker-disease relationships could unlock new therapeutic strategies and allow repurposing of already-approved drugs.
This study employed two-sample Mendelian randomization (MR), a method that uses genetic variants as instrumental variables to infer causality from observational data. Genome-wide association study data were analyzed using multiple complementary MR approaches to minimize bias, then integrated with DrugBank, protein-protein interaction networks, bulk RNA sequencing, and molecular docking to translate statistical signals into actionable drug targets.
Six biomarkers demonstrated causal effects on prostate diseases: uric acid (URK) on prostatitis; gamma-glutamyl transferase (GGT) and total bilirubin (TBIL) on BPH; and uric acid-to-creatinine ratio (UCR), phosphorus (PHOS), and blood urea nitrogen (BUN) on prostate cancer. Downstream functional analyses highlighted myeloperoxidase (MPO) and tubulin beta (TUBB) as druggable targets for BPH, and MET and ATP8B1 were also implicated. For prostate cancer, GATA3 and ENPP3 emerged as novel molecular targets.
Drug repurposing predictions suggested dexamethasone as a candidate therapy for BPH and colchicine and metformin as potential agents against prostate cancer — all drugs with established safety profiles that could accelerate clinical translation.
These findings provide a genetically informed framework for understanding prostate disease biology. However, results are limited by the scope of available GWAS data and the computational nature of molecular docking. Experimental validation in cell and animal models, followed by clinical trials, will be essential before these repurposing candidates can be adopted in practice.
Key Findings
- Six circulating biomarkers causally linked to prostatitis, BPH, or prostate cancer via Mendelian randomization.
- MPO and TUBB identified as novel druggable targets for benign prostatic hyperplasia.
- GATA3 and ENPP3 implicated as therapeutic targets in prostate cancer via molecular docking.
- Dexamethasone flagged as a repurposing candidate for BPH; colchicine and metformin for prostate cancer.
- Integration of GWAS, protein networks, and RNA-seq strengthens causal inference for drug target discovery.
Methodology
Two-sample Mendelian randomization was performed using genome-wide association data with multiple MR methods to estimate causal effects. Findings were further integrated with DrugBank, protein-protein interaction networks, bulk RNA sequencing, and computational molecular docking to identify and validate drug targets.
Study Limitations
The study relies on GWAS summary statistics, limiting the ability to account for all confounders or population diversity. Molecular docking is computational and requires wet-lab and in vivo validation. Causal biomarker relationships may not translate directly into effective therapeutic interventions without clinical trial confirmation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.